Skip to content
Screener

Summit Therapeutics SMMT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Merck & Co. logo
Merck & Co.MRK
$128.69B+11.8%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$924M-14.0%
Nuvation Bio logo
Nuvation BioNUVB
$744.5M+15.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$183.97M-24.2%
Incyte logo
IncyteINCY
$7.87B+35.2%

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.79B-49.0%
Enterprise value$10.81B-49.0%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 5:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001599298-26-000039
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively7,7607,754
Additional paid-in capital3,024,3872,947,805
Accumulated other comprehensive loss(2,632)(2,540)
Accumulated deficit(2,483,583)(2,294,159)
Total stockholders' equity545,932658,860
Total liabilities and stockholders' equity$647,856$751,182

Item 1. Financial Statements.

FAQ

What is Summit Therapeutics's total liabilities & equity?
Summit Therapeutics (SMMT) reported total liabilities & equity of $647.86M in Q1 2026.
How has Summit Therapeutics's total liabilities & equity changed year-over-year?
Summit Therapeutics's total liabilities & equity increased by 68.8% year-over-year, from $383.82M to $647.86M.
What is the long-term trend for Summit Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Summit Therapeutics's total liabilities & equity has grown at a 48.9% compound annual growth rate (CAGR), from $102.5M to $751.18M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Summit Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude